Cardiovascular Outcomes in Patients on Hemodialysis following Drug-Eluting versus Bare-Metal Coronary Stents

Table 4

Outcomes at 30 days: bivalirudin versus heparin in patients with ESRD undergoing PCI.

	Bivalirudin ()	UFH/LMWH only ()	value
	n (%)	n (%)
Bleeding	NA^‡	9 (5%)	0.95
Mortality	NA	19 (10%)	0.11
MI	NA	15 (8%)	0.94
Heart failure	NA	NA	NA
Stroke^†	0 (0%)	0 (0%)	NA
TVR	0 (0%)	NA	NA
Composite^,†	10 (15%)	35 (18%)	0.55
Composite BMS	2 (12/68)	8 (43/196)	0.88
Composite DES	8 (56/68)	27 (153/196)	0.57

Any of the following 30-day outcomes: mortality, MI, heart failure, stroke, or TVR; ^†no stroke events were reported in either group; ^‡if there are fewer than 7 cases/events, the exact number is not disclosed per the Massachusetts Department of Public Health; ESRD, end-stage renal disease; PCI, percutaneous coronary intervention; UFH, unfractionated heparin; LMWH, low molecular weight heparin; MI, myocardial infarction; TVR, target vessel revascularization; NA, not available; BMS, bare-metal stent; DES, drug-eluting stent.